BMS-986435

DRUG5 trials

Sponsors

Bristol-Myers Squibb

Conditions

Healthy ParticipantsHealthy VolunteersHeart FailureHepatic Impairment

Phase 1

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Drug Effects of Single Doses of BMS-986435 (MYK-224) in Healthy Chinese Participants

CompletedNCT06476821

Bristol-Myers SquibbHealthy Volunteers

Start: 2024-06-27End: 2024-10-11Updated: 2024-11-19

Study to Assess Relative Bioavailability of BMS-986435 Formulations in Healthy Adult Participants

CompletedNCT06577259

Bristol-Myers SquibbHealthy Participants

Start: 2024-09-03End: 2025-02-19Updated: 2025-03-14

A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants

RecruitingNCT07226817

Bristol-Myers SquibbHealthy Volunteers

Start: 2025-11-12End: 2026-12-17Target: 240Updated: 2026-08-12

A Study to Assess the Drug Levels and Safety of BMS-986435 in Participants With Normal Hepatic Function and Participants With Different Degrees of Hepatic Impairment

RecruitingNCT07248839

Bristol-Myers SquibbHealthy Volunteers, Hepatic Impairment

Start: 2025-12-15End: 2026-08-05Target: 24Updated: 2026-06-12

Phase 2

Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)

Active, not recruitingNCT06122779

Bristol-Myers SquibbHeart Failure

Start: 2023-11-07End: 2026-12-14Updated: 2026-07-30